$RLAY
Relay Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022021892 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $253.0K $344.0K $567.0K
YoY Change -55.38% -48.35% -99.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.47M $16.07M $15.55M
YoY Change 5.92% 9.48% 0.05%
% of Gross Profit
Research & Development $67.28M $66.90M $51.08M
YoY Change 31.7% 51.47% 62.58%
% of Gross Profit
Depreciation & Amortization $1.166M $1.033M $1.034M
YoY Change 12.77% 2.08% 13.63%
% of Gross Profit
Operating Expenses $73.10M $86.24M $68.29M
YoY Change 7.05% 39.87% 43.26%
Operating Profit -$85.89M
YoY Change 40.83%
Interest Expense $5.372M $1.713M $267.0K
YoY Change 1911.99% 991.08% -11.0%
% of Operating Profit
Other Income/Expense, Net -$24.00K $1.720M $0.00
YoY Change 995.54% -100.0%
Pretax Income -$67.50M -$84.17M -$67.46M
YoY Change 0.07% 38.37% -291.2%
Income Tax
% Of Pretax Income
Net Earnings -$67.50M -$84.17M -$67.46M
YoY Change 0.07% 38.37% -291.2%
Net Earnings / Revenue -26681.03% -24468.6% -11897.0%
Basic Earnings Per Share -$0.76
Diluted Earnings Per Share -$0.56 -$0.76 -$656.5K
COMMON SHARES
Basic Shares Outstanding 120.9M 108.9M
Diluted Shares Outstanding 110.9M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $998.9M $1.054B $958.1M
YoY Change 4.26% 70.93% 41.29%
Cash & Equivalents $151.8M $354.6M $280.1M
Short-Term Investments $847.1M $699.1M $678.0M
Other Short-Term Assets $3.259M $11.58M $13.23M
YoY Change -75.36% -34.56% 40.73%
Inventory
Prepaid Expenses $12.11M $16.81M $11.47M
Receivables $306.0K $241.0K $403.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.020B $1.087B $976.2M
YoY Change 4.43% 70.09% 26.77%
LONG-TERM ASSETS
Property, Plant & Equipment $11.63M $11.39M $6.543M
YoY Change 77.81% -58.55% 4.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.578M $2.578M $2.578M
YoY Change 0.0% 0.0% 186.44%
Total Long-Term Assets $80.27M $81.42M $32.20M
YoY Change 149.27% 151.64% 8.32%
TOTAL ASSETS
Total Short-Term Assets $1.020B $1.087B $976.2M
Total Long-Term Assets $80.27M $81.42M $32.20M
Total Assets $1.100B $1.169B $1.008B
YoY Change 9.06% 74.02% 26.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.58M $9.485M $8.276M
YoY Change 27.82% 50.17% 30.31%
Accrued Expenses $22.70M $29.36M $13.56M
YoY Change 67.46% 34.25% 135.36%
Deferred Revenue $248.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $63.71M $71.43M $24.32M
YoY Change 161.95% 150.47% 78.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $85.84M $97.52M $15.00M
YoY Change 472.29% 35.43% -34.5%
Total Long-Term Liabilities $85.84M $97.52M $15.00M
YoY Change 472.29% 35.43% -34.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $63.71M $71.43M $24.32M
Total Long-Term Liabilities $85.84M $97.52M $15.00M
Total Liabilities $149.6M $168.9M $110.6M
YoY Change 35.18% 68.06% 202.81%
SHAREHOLDERS EQUITY
Retained Earnings -$1.100B -$991.1M -$768.1M
YoY Change 43.21% 41.46% 90.02%
Common Stock $121.0K $121.0K $109.0K
YoY Change 11.01% 21.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $950.2M $999.8M $897.8M
YoY Change
Total Liabilities & Shareholders Equity $1.100B $1.169B $1.008B
YoY Change 9.06% 74.02% 26.08%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income -$67.50M -$84.17M -$67.46M
YoY Change 0.07% 38.37% -291.2%
Depreciation, Depletion And Amortization $1.166M $1.033M $1.034M
YoY Change 12.77% 2.08% 13.63%
Cash From Operating Activities -$57.08M -$66.14M -$39.71M
YoY Change 43.75% 24.34% 12.58%
INVESTING ACTIVITIES
Capital Expenditures $2.316M -$2.095M -$880.0K
YoY Change -363.18% 20.68% 1366.67%
Acquisitions
YoY Change
Other Investing Activities -$144.6M $29.28M -$291.9M
YoY Change -50.45% 30.01% 282.22%
Cash From Investing Activities -$146.9M $27.19M -$292.7M
YoY Change -49.81% 30.79% 283.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.166M 285.9M 384.0M
YoY Change -99.7% 31592.35% 639920.0%
NET CHANGE
Cash From Operating Activities -57.08M -66.14M -39.71M
Cash From Investing Activities -146.9M 27.19M -292.7M
Cash From Financing Activities 1.166M 285.9M 384.0M
Net Change In Cash -202.8M 246.9M 51.56M
YoY Change -493.42% -883.58% -146.19%
FREE CASH FLOW
Cash From Operating Activities -$57.08M -$66.14M -$39.71M
Capital Expenditures $2.316M -$2.095M -$880.0K
Free Cash Flow -$59.40M -$64.05M -$38.83M
YoY Change 52.97% 24.46% 10.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2591000
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3923475
dei Entity Address Address Line1
EntityAddressAddressLine1
399 Binney Street
dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Central Index Key
EntityCentralIndexKey
0001812364
dei Entity File Number
EntityFileNumber
001-39385
dei Entity Registrant Name
EntityRegistrantName
RELAY THERAPEUTICS, INC.
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6746000
CY2021Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
370-8837
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RLAY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
120894901
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
354643000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
280119000
CY2022Q3 us-gaap Investments
Investments
699149000
CY2021Q4 us-gaap Investments
Investments
677954000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
241000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
403000
CY2022Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4876000
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4537000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
16808000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11465000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
11580000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1764000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
1087297000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
976242000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11390000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6543000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
65153000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20780000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2578000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2578000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2300000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2300000
CY2022Q3 us-gaap Assets
Assets
1168718000
CY2021Q4 us-gaap Assets
Assets
1008443000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9485000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8276000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29360000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13557000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5681000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1844000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
248000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
26901000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
396000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
71427000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24321000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
54600000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21056000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
42922000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
50258000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
15000000
CY2022Q3 us-gaap Liabilities
Liabilities
168949000
CY2021Q4 us-gaap Liabilities
Liabilities
110635000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
120811215
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
120811215
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
108210318
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
108210318
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
121000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
109000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2004143000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1666887000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13389000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1088000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-991106000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-768100000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
999769000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
897808000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1168718000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1008443000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
344000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
666000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1128000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2462000
CY2022Q3 us-gaap Revenues
Revenues
344000
CY2021Q3 us-gaap Revenues
Revenues
666000
us-gaap Revenues
Revenues
1128000
us-gaap Revenues
Revenues
2462000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
66900000
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
44974000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
179078000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
120743000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
123000000
us-gaap Variable Interest Entity Initial Consolidation Gain Or Loss
VariableInterestEntityInitialConsolidationGainOrLoss
-11855000
CY2022Q3 rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
3262000
CY2021Q3 rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
2000000
rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1133000
rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
2000000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16074000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14682000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
49607000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41839000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
86236000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
61656000
us-gaap Operating Expenses
OperatingExpenses
227552000
us-gaap Operating Expenses
OperatingExpenses
299437000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-85892000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-60990000
us-gaap Operating Income Loss
OperatingIncomeLoss
-226424000
us-gaap Operating Income Loss
OperatingIncomeLoss
-296975000
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
1713000
CY2021Q3 us-gaap Interest Income Other
InterestIncomeOther
157000
us-gaap Interest Income Other
InterestIncomeOther
3414000
us-gaap Interest Income Other
InterestIncomeOther
563000
CY2022Q3 rlay Other Income Expense
OtherIncomeExpense
7000
rlay Other Income Expense
OtherIncomeExpense
4000
rlay Other Income Expense
OtherIncomeExpense
-4000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1720000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
157000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3418000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
559000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-84172000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-60833000
us-gaap Net Income Loss
NetIncomeLoss
-223006000
us-gaap Net Income Loss
NetIncomeLoss
-296416000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.20
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
110905940
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110905940
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92692515
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92692515
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109290743
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109290743
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92599781
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92599781
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-1483000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
74000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-12301000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-54000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1483000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
74000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-12301000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-54000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-85655000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60759000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-235307000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-296470000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
897808000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
883000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13455000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-8130000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-62046000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
841970000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
859000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1137000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15147000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-2688000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-76788000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
779637000
CY2022Q3 rlay Issuance Of Common Stock Upon Milestone Achievement
IssuanceOfCommonStockUponMilestoneAchievement
6203000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
284744000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1121000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13719000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-1483000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-84172000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
999769000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
763293000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2055000
CY2021Q1 rlay Vesting Of Restricted Common Stock Value
VestingOfRestrictedCommonStockValue
3000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9671000
CY2021Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-52000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-42184000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
732786000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1123000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16147000
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
61948000
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-76000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-193399000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
618529000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
900000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12418000
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
74000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-60833000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
571088000
us-gaap Net Income Loss
NetIncomeLoss
-223006000
us-gaap Net Income Loss
NetIncomeLoss
-296416000
us-gaap Share Based Compensation
ShareBasedCompensation
42321000
us-gaap Share Based Compensation
ShareBasedCompensation
38236000
us-gaap Depreciation
Depreciation
2964000
us-gaap Depreciation
Depreciation
2891000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1567000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1371000
rlay Acquired Research And Development In Process
AcquiredResearchAndDevelopmentInProcess
123000000
us-gaap Variable Interest Entity Initial Consolidation Gain Or Loss
VariableInterestEntityInitialConsolidationGainOrLoss
-11855000
rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1133000
rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
2000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-162000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-74276000
us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
339000
us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
-3403000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
15159000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
7147000
rlay Increase Decrease In Operating Lease Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet
6992000
rlay Increase Decrease In Operating Lease Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet
-231000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-22000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
22000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1503000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
27430000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
13082000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-248000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-172411000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34699000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
207778000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
653633000
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
172715000
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
494673000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
25215000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41809000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-186766000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2863000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4078000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1137000
rlay Proceeds From Issuance Of Common Stock Upon Follow On Offering Net
ProceedsFromIssuanceOfCommonStockUponFollowOnOfferingNet
284744000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
288744000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4078000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
74524000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-217387000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
282697000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
448524000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357221000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
231137000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1065000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
33000
rlay Reclassification Of Restricted Stock Liability To Additional Paid In Capital
ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital
3000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
662000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
2330000
us-gaap Stock Issued1
StockIssued1
62990000
rlay Issuance Of Common Stock Upon Milestone Achievement
IssuanceOfCommonStockUponMilestoneAchievement
6203000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
46626000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
354643000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228559000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
2578000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
2578000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357221000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
231137000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-991100000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
42922000
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
50465000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
42922000
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
50465000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the fair value of contingent milestone payments in connection with the acquisition of ZebiAI Therapeutics, Inc. (“ZebiAI”), the determination of the transaction price and standalone selling price of performance obligations under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ("ASC 606"), the accrual of research and development and manufacturing expenses, the valuation of equity instruments, and the incremental borrowing rate for determining operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
12612000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
58278000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
781000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
689378000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
13393000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
45863000
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
48465000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
50258000
rlay Fair Value Of Contingent Milestone Payments Upon Acquisition
FairValueOfContingentMilestonePaymentsUponAcquisition
48465000
CY2022Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3262000
CY2021Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2000000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1133000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2000000
CY2022Q3 rlay Common Stock Issued Upon Milestone Achievement
CommonStockIssuedUponMilestoneAchievement
6203000
rlay Common Stock Issued Upon Milestone Achievement
CommonStockIssuedUponMilestoneAchievement
6203000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
712538000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13393000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
699149000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
679042000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1088000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
677954000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
110
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
88
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
631100000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
677954000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1088000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
677954000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1088000
CY2022Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4900000
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4500000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the stockholder to one vote on all matters submitted to a vote of the Company’s stockholders.
us-gaap Dividends Common Stock
DividendsCommonStock
0
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92599781
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13719000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12418000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42321000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38236000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-84172000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-60833000
us-gaap Net Income Loss
NetIncomeLoss
-223006000
us-gaap Net Income Loss
NetIncomeLoss
-296416000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.20
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
110905940
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110905940
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92692515
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92692515
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109290743
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109290743
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92599781
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12811599
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12811599
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9544443
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9544443

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-22-021892-index-headers.html Edgar Link pending
0000950170-22-021892-index.html Edgar Link pending
0000950170-22-021892.txt Edgar Link pending
0000950170-22-021892-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rlay-20220930.htm Edgar Link pending
rlay-20220930.xsd Edgar Link pending
rlay-ex31_1.htm Edgar Link pending
rlay-ex31_2.htm Edgar Link pending
rlay-ex32_1.htm Edgar Link pending
Show.js Edgar Link pending
rlay-20220930_def.xml Edgar Link unprocessable
rlay-20220930_pre.xml Edgar Link unprocessable
rlay-20220930_lab.xml Edgar Link unprocessable
rlay-20220930_cal.xml Edgar Link unprocessable
rlay-20220930_htm.xml Edgar Link completed